Skip to main content

Table 5 Sensitivity to discount rates and coverage in risk groups

From: Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study

a) 3.5 % discount (Base case)

Extension to

2–4

50–64

5–16

2–4 + 50–64

2–16

2–16 + 50–64

2–64

ICER

2613

7350

1745

5637

1949

3073

5046

Net benefit in mil £

74

91

460

164

521

604

819

Lower

12

–8

94

9

104

93

65

Higher

266

385

1577

614

1785

2107

3046

b) 1.5 % discount

Extension to

2–4

50–64

5–16

2–4 + 50–64

2–16

2–16 + 50–64

2–64

ICER

2509

7030

1675

5398

1869

2943

4818

Net benefit

79

99

487

177

551

642

875

Lower

15

–2

115

17

126

118

108

Higher

272

394

1615

626

1820

2141

3090

c) 0 % discount

Extension to

2–4

50–64

5–16

2–4 + 50–64

2–16

2–16 + 50–64

2–64

ICER

2406

6715

1604

5162

1788

2813

4590

Net benefit

83

107

515

190

584

680

941

Lower

18

3

135

25

148

153

159

Higher

276

401

1643

639

1864

2174

3139

d) Risk groups vaccinated with a 75 % coverage

Extension to

2–4

50–64

5–16

2–4 + 50–64

2–16

2–16 + 50–64

2–64

ICER

2748

8677

2393

6655

2618

3844

6667

Net benefit

72

86

417

158

463

520

592

Lower

11

–17

71

–3

75

59

–17

Higher

258

381

1438

600

1607

1847

2411

  1. Cost-effectiveness ratios (compared with the elderly- and risk-group strategy) and net benefits with associated 95 % credibility intervals using different discount rates (a–c) for future benefits (QALYs) and a different baseline (d) for the coverage in risk-groups (75 %)
  2. ICER, Incremental cost effectiveness ratio